Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Objective 5  

$15,879,826.98
Fiscal Year: 2008

Green dot: Objective has greater than or equal to the recommended funding.4.5 Standardize and validate at least 20 model systems (e.g. cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.

Download 2008 Question 4: Objective 5 projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
A non-human primate autism model based on maternal infection Patterson, Paul California Institute of Technology
Role of Wnt signaling through Dishevelled, Dact and p120catenin in forebrain development, synaptic physiology, and mouse behavior: Exploration of a pathway with many components linked to autism spectrum disorders Reichardt, Louis University of California, San Francisco
Perturbed activity dependent plasticity mechanisms in autism Sabatini, Bernardo Harvard Medical School
Models and mechanisms - 2 Sahin, Mustafa Boston Children's Hospital
Oxidative stress: Rat study Sajdel-Sulkowska, Ellen Brigham and Women's Hospital
Connectopathic analysis of autism Sanes, Joshua Harvard University
Genetic analyses of ARX homeobox gene function in neurodevelopmental disorders Sengupta, Piali Brandeis University
Mice lacking Shank postsynaptic scaffolds as an animal model of autism Sheng, Morgan Massachusetts Institute of Technology
Using zebrafish and chemical screening to define function of autism genes Sive, Hazel Whitehead Institute for Biomedical Research
Function and dysfunction of neuroligins Sudhof, Thomas Stanford University
Aberrant synaptic function due to TSC mutation in autism Sulzer, David Columbia University Medical Center
Models and mechanisms - 1 Sur, Mriganka Massachusetts Institute of Technology
Neural and cognitive mechanisms of autism Sur, Mriganka Massachusetts Institute of Technology
Cognitive mechanisms of serially organized behavior Terrace, Herbert Columbia University
Regulation of synaptogenesis by cyclin dependent kinase 5 Tsai, Li-Huei Massachusetts Institute of Technology
Probing a monogenic form of autism from molecules to behavior Tsien, Richard Stanford University
Regulation of gene expression in the brain Young, Walter National Institutes of Health

Objective Cumulative Funding Table

IACC Strategic Plan Objectives 2008 2009 2010 2011 2012 Total
Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.

IACC Recommended Budget: $75,000,000 over 5 years
4.5
$15,879,827
42 projects

4.S.B
$20,162,709
70 projects

4.S.B
$23,229,501
92 projects

4.S.B
$21,606,118
89 projects

4.S.B
$21,232,514
94 projects

$102,110,669
4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

Progress: More than 90 projects were supported to develop animal models.

Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built.  The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.